sulfinpyrazone has been researched along with Cardiovascular Stroke in 191 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Platelet studies were performed during a controlled double-blind randomized clinical trial of sulfinpyrazone (Anturane Reinfarction Trial) in 41 patients who had recent myocardial infarction." | 9.05 | Sulfinpyrazone decreases epinephrine-induced platelet aggregation after myocardial infarction. ( Bourassa, MG; Latour, JG; Theroux, P, 1982) |
| "The results of the Anturane Reinfarction Trial, a randomized, double-blind, multicenter clinical trial, represent the data on 1558 patients who received either sulfinpyrazone or placebo for an average of 16 months, starting 25 to 35 days after a documented myocardial infarction." | 9.05 | [Sulfinpyrazone in the prevention of sudden death after myocardial infarction (author's transl)]. ( Sherry, S, 1980) |
| "We report the results of a randomized double-blind, multicenter trial comparing sulfinpyrazone (200 mg four times a day) and a placebo in the prevention of cardiac mortality among 1558 patients followed for an average of 16 months, beginning 25 to 35 days after a documented myocardial infarction." | 9.05 | Sulfinpyrazone in the prevention of sudden death after myocardial infarction. ( , 1980) |
| "Preliminary data obtained in the ambit of Anturan Reinfarction Italian Study (ARIS) show that, in postmyocardial infarction, reduced platelet survival time occurred in hyperbetalipoproteinemic patients treated with placebo, but not in the group of patients treated with sulfinpyrazone (interaction between treatment and lipemic level is at p approximately equal to 0." | 9.04 | A controlled study of the effect of sulfinpyrazone on platelet survival and on platelet-bound 14C-serotonin release in patients with previous myocardial infarction. ( Basagni, M; Boschetti, C; Cortellaro, M; Fassio, G; Polli, EE, 1979) |
| "The Anturane Reinfarction Trial is a randomized, double-blind, multicenter clinical trial comparing sulfinpyrazone (200 mg four times a day) and placebo in the prevention of cardiac mortality among patients with a recent documented myocardial infarction." | 9.04 | Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. The Anturane Reinfarction Trial. ( , 1978) |
| "Single intravenous injection of adrenochrome (10 to 50 mg/kg body weight), an oxidation product of catecholamines, has been shown to induce arrhythmias and cause death in anesthetized rats in a dose-dependent manner." | 7.66 | Protective effect of sulfinpyrazone against catecholamine metabolite adrenochrome-induced arrhythmias. ( Beamish, RE; Dhalla, NS; Dhillon, KS; Singal, PK, 1981) |
| "Prophylactic effects of sulfinpyrazone (100 mg/Kg), aspirin (5 mg/Kg, 50 mg/Kg), and propranolol (2 mg/Kg, 10 mg/Kg) on myocardial necrosis and hypertrophy induced by isoproterenol were examined." | 7.66 | Effects of sulfinpyrazone, aspirin and propranolol on the isoproterenol-induced myocardial necrosis. ( Hashimoto, H; Ogawa, K, 1981) |
| " A recent double-blind multicenter trial ("Anturane Reinfarction Trial") showed that the incidence of sudden cardiac death was reduced in Sulfinpyrazone-treated patients after acute myocardial infarction compared with the placebo group, although the rate of reinfarctions was not diminished." | 7.66 | [Effects of sulfinpyrazone on early ventricular fibrillation and 2d-phase arrhythmias in acute myocardial infarction (author's transl)]. ( Bender, F; Dorsel, T; Gülker, H; Heuer, H; Kristek, J; Pierchalla, P; Thale, J, 1980) |
| "The sulfinpyrazone treatment subsample presented normalized PPT accompanied by reduction of VIII:RAg but not of beta-TG or PF4 levels." | 6.65 | In vivo platelet hyperactivity and factor VIII related antigen increase long after myocardial infarction. A controlled effect of sulfinpyrazone. ( Beggi, P; Boschetti, C; Cortellaro, M; Polli, EE, 1981) |
| "Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (it may possibly be beneficial to women also), myocardial infarction and death in patients with unstable angina, thromboembolic complications associated with artificial heart valves in patients receiving oral anticoagulants (although gastrointestinal bleeding is prohibitive with this combination), and thrombotic occlusion of silicone rubber arteriovenous cannulae in uremic patients undergoing hemodialysis." | 6.15 | Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. ( Harker, LA, 1986) |
| "Pretreatment with sulfinpyrazone reduced isoproterenol-induced lesions by 42%." | 5.26 | Reduction in the severity of myocardial infarction by sulfinpyrazone. ( Innes, IR; Weisman, H, 1981) |
| "Aspirin, sulfinpyrazone and the combination of aspirin/dipyridamole, which inhibit some aspects of platelet function, have been evaluated in large-scale clinical trials in secondary prevention of myocardial infarction." | 5.05 | Secondary prevention of myocardial infarction. ( Davies, JA, 1985) |
| "The Anturane Reinfarction Trial evaluated the effect of sulfinpyrazone (Anturane) (200 mg four times a day) vs placebo on cardiac mortality rates among patients recently recovered from an acute myocardial infarction." | 5.05 | The anturane reinfarction trial. ( Sherry, S, 1980) |
| "Platelet studies were performed during a controlled double-blind randomized clinical trial of sulfinpyrazone (Anturane Reinfarction Trial) in 41 patients who had recent myocardial infarction." | 5.05 | Sulfinpyrazone decreases epinephrine-induced platelet aggregation after myocardial infarction. ( Bourassa, MG; Latour, JG; Theroux, P, 1982) |
| "The results of the Anturane Reinfarction Trial, a randomized, double-blind, multicenter clinical trial, represent the data on 1558 patients who received either sulfinpyrazone or placebo for an average of 16 months, starting 25 to 35 days after a documented myocardial infarction." | 5.05 | [Sulfinpyrazone in the prevention of sudden death after myocardial infarction (author's transl)]. ( Sherry, S, 1980) |
| "The effects of sulphinpyrazone 800 mg daily on renal excretory function were studied in a double-blind placebo-controlled randomised trial of incremental and full doses of the drug in 28 patients with plasma urea concentration less than 10 mmol/l in the period 2-28 days following uncomplicated acute myocardial infarction." | 5.05 | Sulphinpyrazone and renal function following myocardial infarction. ( Choudhury, SL; Morgan, DB; Swaminathan, R; Taylor, SH; Wieringa, G, 1983) |
| "We report the results of a randomized double-blind, multicenter trial comparing sulfinpyrazone (200 mg four times a day) and a placebo in the prevention of cardiac mortality among 1558 patients followed for an average of 16 months, beginning 25 to 35 days after a documented myocardial infarction." | 5.05 | Sulfinpyrazone in the prevention of sudden death after myocardial infarction. ( , 1980) |
| " These trials were prompted by earlier observations that aspirin takers seemed to fare better after acute myocardial infarction and were further stimulated by the recent growth of knowledge about the role of vascular and platelet prostaglandins." | 5.05 | Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials. ( Castaldi, PA, 1981) |
| "Preliminary data obtained in the ambit of Anturan Reinfarction Italian Study (ARIS) show that, in postmyocardial infarction, reduced platelet survival time occurred in hyperbetalipoproteinemic patients treated with placebo, but not in the group of patients treated with sulfinpyrazone (interaction between treatment and lipemic level is at p approximately equal to 0." | 5.04 | A controlled study of the effect of sulfinpyrazone on platelet survival and on platelet-bound 14C-serotonin release in patients with previous myocardial infarction. ( Basagni, M; Boschetti, C; Cortellaro, M; Fassio, G; Polli, EE, 1979) |
| "The Anturane Reinfarction Trial is a randomized, double-blind, multicenter clinical trial comparing sulfinpyrazone (200 mg four times a day) and placebo in the prevention of cardiac mortality among patients with a recent documented myocardial infarction." | 5.04 | Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. The Anturane Reinfarction Trial. ( , 1978) |
| "1) Myocardial infarction (MI): Aspirin (160-300 mg/day) therapy started immediately after the onset, with or without simultaneous coronary arterial thrombolytic therapy, reduces the mortality rate in vascular diseases, including MI, and prevents reinfarction." | 3.68 | [Antiplatelet therapy in cardiac diseases]. ( Aosaki, M; Hosoda, S; Iwade, K; Kimata, S, 1992) |
| "Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death." | 3.67 | Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. ( Borhani, NO, 1985) |
| " Seven recently completed clinical trials, the Coronary Drug Project, the Aspirin Myocardial Infarction Study, the Anturane Reinfarction Trial, the Hypertension Detection and Follow-Up Program and three drug trials of betablockers, are reviewed from the perspective of both their clinical and methodological significance." | 3.66 | Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease. ( Friedewald, WT; Schoenberger, JA, 1982) |
| "Prophylactic effects of sulfinpyrazone (100 mg/Kg), aspirin (5 mg/Kg, 50 mg/Kg), and propranolol (2 mg/Kg, 10 mg/Kg) on myocardial necrosis and hypertrophy induced by isoproterenol were examined." | 3.66 | Effects of sulfinpyrazone, aspirin and propranolol on the isoproterenol-induced myocardial necrosis. ( Hashimoto, H; Ogawa, K, 1981) |
| " A recent double-blind multicenter trial ("Anturane Reinfarction Trial") showed that the incidence of sudden cardiac death was reduced in Sulfinpyrazone-treated patients after acute myocardial infarction compared with the placebo group, although the rate of reinfarctions was not diminished." | 3.66 | [Effects of sulfinpyrazone on early ventricular fibrillation and 2d-phase arrhythmias in acute myocardial infarction (author's transl)]. ( Bender, F; Dorsel, T; Gülker, H; Heuer, H; Kristek, J; Pierchalla, P; Thale, J, 1980) |
| "Two cases with acute reversible renal failure while receiving sulfinpyrazone after acute myocardial infarction are presented." | 3.66 | Non oliguric acute renal failure after treatment with sulfinpyrazone. ( Ben Ari, J; Grenadier, E; Keidar, S; Kohan, R; Levy, J; Palant, A, 1982) |
| "Four non-steroid anti-inflammatory drugs, sulfinpyrazone, acetylsalicylic acid, sodium salicylate and indomethacin were tested in the acute phase of experimental myocardial infarction in conscious rats." | 3.66 | Effect of non-steroid anti-inflammatory drugs in experimental myocardial infarction in rats. ( Koltai, M; Leprán, I; Szekeres, L, 1981) |
| "Single intravenous injection of adrenochrome (10 to 50 mg/kg body weight), an oxidation product of catecholamines, has been shown to induce arrhythmias and cause death in anesthetized rats in a dose-dependent manner." | 3.66 | Protective effect of sulfinpyrazone against catecholamine metabolite adrenochrome-induced arrhythmias. ( Beamish, RE; Dhalla, NS; Dhillon, KS; Singal, PK, 1981) |
| "The sulfinpyrazone treatment subsample presented normalized PPT accompanied by reduction of VIII:RAg but not of beta-TG or PF4 levels." | 2.65 | In vivo platelet hyperactivity and factor VIII related antigen increase long after myocardial infarction. A controlled effect of sulfinpyrazone. ( Beggi, P; Boschetti, C; Cortellaro, M; Polli, EE, 1981) |
| " It is concluded that when initiating and withdrawing treatment with SP in a patient receiving AC, the prothrombin time should be checked daily for a few days to adapt (reduce) the dosage of AC to the change in prothrombin time induced by SP." | 2.65 | [The effect of sulfinpyrazone on the coagulation-inhibiting action of acenocoumarol]. ( Fontanilles, F; Holt, NF; Michot, F, 1981) |
| "273 patients suffering from ischemic heart disease were treated with Anturan for one year at a daily dosage of 800 mg." | 1.27 | Anturan for secondary prophylaxis of myocardial infarction. ( Bokarev, IN; Golikov, AP; Lusov, VA; Ptushkin, VV; Savenkov, MP; Seregina, MV; Zvereva, TV, 1988) |
| "Sulfinpyrazone treatment of patients with myocardial infarction (Killip--classification I and II), starting 25--35 days after the acute myocardial infarction, reduces cardiac mortality and incidence of sudden death for a period of two years." | 1.26 | [Action mechanism and clinical indications for thrombocyte aggregation inhibitors]. ( Oelz, O, 1979) |
| "and sulfinpyrazone have been tested in several large scale clinical trials." | 1.26 | [Antiplatelet drugs (author's transl)]. ( Dechavanne, M; Follea, G; Trzeciak, MC, 1979) |
| "We report on 4 cases of reversible acute renal failure (ARF), appearing within the first days after institution of a sulfinpyrazone treatment (600 mg p." | 1.26 | [Acute renal failure induced by sulfinpyrazone (author's transl)]. ( Boelaert, J; Daneels, R; Dard, S; El Nahas, M; Kourilsky, O; Meyrier, A; Morel-Maroger, L; Sraer, JD; Van Eeghem, P, 1981) |
| "Pretreatment with sulfinpyrazone reduced isoproterenol-induced lesions by 42%." | 1.26 | Reduction in the severity of myocardial infarction by sulfinpyrazone. ( Innes, IR; Weisman, H, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 186 (97.38) | 18.7374 |
| 1990's | 4 (2.09) | 18.2507 |
| 2000's | 1 (0.52) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| SMYTHE, HA | 1 |
| OGRYZLO, MA | 1 |
| MURPHY, EA | 1 |
| MUSTARD, JF | 2 |
| HILLECKE, NA | 1 |
| Fleming, JS | 1 |
| Buyniski, JP | 1 |
| Simon, JA | 1 |
| Braunwald, E | 1 |
| Ritter, JM | 1 |
| Walter, E | 2 |
| Staiger, C | 1 |
| Rothlin, M | 1 |
| Boissel, JP | 2 |
| Leizorovicz, A | 2 |
| Faucomprez, C | 1 |
| McNicol, GP | 1 |
| Brunner, L | 1 |
| Stepanek, J | 1 |
| Brunner, H | 1 |
| Genton, E | 3 |
| Schröder, R | 2 |
| Perrenoud, JJ | 1 |
| Kallio, V | 1 |
| de Bono, DP | 1 |
| Hitzenberger, G | 1 |
| Gross, F | 1 |
| Greco, R | 1 |
| Siciliano, S | 1 |
| Gentile, F | 1 |
| Elia, L | 1 |
| Murena, E | 1 |
| Forni, N | 1 |
| Boccalatte, A | 1 |
| Marsico, F | 1 |
| Friedewald, WT | 1 |
| Schoenberger, JA | 1 |
| Toshima, H | 1 |
| Adachi, K | 1 |
| Spann, JF | 1 |
| Kelton, JG | 2 |
| Offerhaus, L | 1 |
| Racco, F | 1 |
| Palermo, R | 1 |
| Agostinelli, MC | 1 |
| Melappioni, A | 1 |
| Ganzetti, S | 1 |
| Conti, V | 1 |
| Amadio, E | 1 |
| Chodorowski, Z | 1 |
| Dalen, JE | 1 |
| Goldberg, RJ | 1 |
| Gore, JM | 1 |
| Struckus, J | 1 |
| Smith, JW | 1 |
| Hirsh, J | 7 |
| Bolte, HD | 2 |
| Hughes, A | 1 |
| Daunt, S | 1 |
| Vass, G | 1 |
| Wickes, J | 1 |
| Buckler, P | 1 |
| Douglas, AS | 1 |
| Thiele, R | 1 |
| Sherry, S | 8 |
| Hashimoto, H | 1 |
| Ogawa, K | 1 |
| Avellone, G | 1 |
| Mandalà, V | 1 |
| Novo, S | 1 |
| Pinto, A | 1 |
| Riolo, FP | 1 |
| Davì, G | 1 |
| Raneli, G | 1 |
| Lijnen, P | 6 |
| Boelaert, J | 7 |
| van Eeghem, P | 5 |
| Daneels, R | 7 |
| Schurgers, M | 5 |
| de Jaegere, P | 1 |
| van der Stichele, E | 1 |
| Vincke, J | 1 |
| Fagard, R | 2 |
| Verschueren, LJ | 3 |
| Amery, A | 5 |
| Castaigne, A | 1 |
| Palsky, E | 1 |
| Benghozi, R | 1 |
| Ledouarin, B | 1 |
| Ordinas, A | 1 |
| Musiał, J | 1 |
| Dworski, R | 1 |
| Szczeklik, A | 1 |
| Cortellaro, M | 5 |
| Boschetti, C | 5 |
| Beggi, P | 1 |
| Polli, EE | 5 |
| Mannucci, PM | 1 |
| Antoniazzi, V | 1 |
| de Gaetano, G | 1 |
| De Blasi, A | 1 |
| Gerna, M | 1 |
| Pezzi, L | 1 |
| Garattini, S | 1 |
| Bulpitt, C | 1 |
| Docci, D | 1 |
| Mambelli, M | 1 |
| Manzoni, G | 1 |
| Turci, F | 1 |
| Salvi, G | 1 |
| Latour, JG | 1 |
| Theroux, P | 1 |
| Bourassa, MG | 1 |
| Van Aken, WG | 1 |
| Verdecchia, P | 1 |
| Fassio, G | 3 |
| Baroni, L | 1 |
| Hampton, JR | 2 |
| Viinikka, L | 1 |
| Toivanen, J | 1 |
| Ylikorkala, O | 1 |
| Choudhury, SL | 1 |
| Taylor, SH | 1 |
| Wieringa, G | 1 |
| Swaminathan, R | 1 |
| Morgan, DB | 1 |
| Karmazyn, M | 1 |
| Moffat, MP | 1 |
| Beamish, RE | 2 |
| Dhalla, NS | 2 |
| Scherrer, JJ | 1 |
| Jackson, JW | 1 |
| Jerde, OM | 1 |
| Poliwoda, H | 1 |
| Selzer, A | 1 |
| Schiff, AA | 1 |
| Meyrier, A | 2 |
| Sraer, JD | 2 |
| Kourilsky, O | 2 |
| Dard, S | 2 |
| El Nahos, M | 1 |
| Shepard, DS | 1 |
| Zeckhauser, RJ | 1 |
| Kolata, GB | 1 |
| Jones, RJ | 1 |
| Hopkins, S | 1 |
| Mitchell, JR | 2 |
| Wilcox, RG | 1 |
| Richardson, D | 1 |
| Banks, DC | 1 |
| Pentecost, BL | 1 |
| Breddin, K | 1 |
| Loew, D | 1 |
| Lechner, K | 1 |
| Uberla, K | 1 |
| Keller, R | 1 |
| Straub, PW | 1 |
| Michot, F | 1 |
| Holt, NF | 1 |
| Fontanilles, F | 1 |
| Kanazawa, T | 1 |
| Matsuoka, H | 1 |
| May, GS | 1 |
| DeMets, DL | 1 |
| Friedman, LM | 1 |
| Furberg, C | 1 |
| Passamani, E | 1 |
| Prentice, CR | 1 |
| Castaldi, PA | 1 |
| Hood, WB | 1 |
| Schbath, J | 1 |
| Destors, JM | 1 |
| Gillet, J | 1 |
| Mayrhofer, EF | 1 |
| Feilhauer, GD | 1 |
| Pilecky, I | 1 |
| Vockner, H | 1 |
| Kühn, P | 1 |
| Keidar, S | 1 |
| Kohan, R | 1 |
| Levy, J | 1 |
| Grenadier, E | 1 |
| Palant, A | 1 |
| Ben Ari, J | 1 |
| Leprán, I | 1 |
| Koltai, M | 1 |
| Szekeres, L | 1 |
| Bolli, R | 1 |
| Goldstein, RE | 1 |
| Davenport, N | 1 |
| Epstein, SE | 1 |
| Dhillon, KS | 1 |
| Singal, PK | 1 |
| Innes, IR | 1 |
| Weisman, H | 1 |
| Howard, T | 1 |
| Hoy, RH | 1 |
| Warren, S | 1 |
| Georgiev, M | 1 |
| Selinger, H | 1 |
| Tulloch, JA | 2 |
| Marr, TC | 2 |
| Morel-Maroger, L | 1 |
| El Nahas, M | 1 |
| Cowan, JC | 1 |
| Williams, EM | 1 |
| Horwitz, DL | 1 |
| Culliton, BJ | 1 |
| Waterfall, WK | 1 |
| Foz, M | 1 |
| Nestel, PJ | 1 |
| Jaeger, S | 1 |
| Berntsen, H | 1 |
| Relman, AS | 2 |
| Temple, R | 1 |
| Pledger, GW | 1 |
| Faergeman, O | 1 |
| Meier, P | 1 |
| Croveri, G | 1 |
| Gülker, H | 1 |
| Bender, F | 1 |
| Thale, J | 1 |
| Heuer, H | 1 |
| Kristek, J | 1 |
| Dorsel, T | 1 |
| Pierchalla, P | 1 |
| Haft, JI | 1 |
| Loo, J | 1 |
| Weston, MJ | 2 |
| Evans, DW | 1 |
| Basagni, M | 2 |
| Verstraete, M | 5 |
| Watt, M | 2 |
| Mertz, DP | 1 |
| Beilin, LJ | 1 |
| Yasunaga, K | 1 |
| Nicholson, MR | 1 |
| Whitlock, RM | 1 |
| Gantmacher, ML | 1 |
| Elwood, PC | 1 |
| Oelz, O | 1 |
| Domenet, J | 1 |
| Caen, JP | 1 |
| Dechavanne, M | 1 |
| Follea, G | 1 |
| Trzeciak, MC | 1 |
| Armitage, P | 1 |
| Blakely, JA | 1 |
| Kane, SH | 1 |
| Green, KG | 1 |
| Stormorken, H | 1 |
| Klimt, CR | 1 |
| Doub, PH | 1 |
| Doub, NH | 1 |
| Weiss, HJ | 1 |
| Gallus, AS | 1 |
| Packham, MA | 1 |
| Kinlough-Rathbone, RL | 1 |
| Gent, M | 3 |
| Harker, LA | 2 |
| Hattori, A | 1 |
| Aosaki, M | 1 |
| Iwade, K | 1 |
| Kimata, S | 1 |
| Hosoda, S | 1 |
| Ferlito, S | 1 |
| Jafri, SM | 1 |
| Bokarev, IN | 2 |
| Lusov, VA | 1 |
| Golikov, AP | 2 |
| Ptushkin, VV | 2 |
| Zvereva, TV | 2 |
| Savenkov, MP | 1 |
| Seregina, MV | 1 |
| Stein, B | 1 |
| Fuster, V | 2 |
| Shalaev, SV | 1 |
| Bélanger, GL | 1 |
| Lavallée, JP | 1 |
| Lenis, J | 1 |
| Ouellet, CA | 1 |
| Borhani, NO | 1 |
| Gelman, JS | 1 |
| Mehta, J | 1 |
| Frishman, WH | 1 |
| Miller, KP | 1 |
| Eller, BT | 1 |
| Lynch, JJ | 1 |
| Patterson, E | 1 |
| Lucchesi, BR | 1 |
| Kubik, MM | 1 |
| Richardson, SG | 1 |
| Cairns, JA | 2 |
| Liusov, VA | 1 |
| Resnekov, L | 1 |
| Chediak, J | 1 |
| Lewis, D | 1 |
| David, JL | 1 |
| Valladares, BK | 1 |
| Lemberg, L | 1 |
| Rühle, H | 1 |
| Singer, J | 1 |
| Finnie, KJ | 1 |
| Froggatt, GM | 1 |
| Holder, DA | 1 |
| Jablonsky, G | 1 |
| Kostuk, WJ | 1 |
| Melendez, LJ | 1 |
| Myers, MG | 1 |
| Davies, JA | 1 |
| Jouve, R | 1 |
| Larrue, J | 1 |
| Gormsen, J | 1 |
| Andersen, LA | 1 |
| Didisheim, P | 1 |
| Kazmier, FJ | 1 |
41 reviews available for sulfinpyrazone and Cardiovascular Stroke
| Article | Year |
|---|---|
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
[Secondary prevention following myocardial infarct. Platelet aggregation inhibitors, beta receptor blockers, antiarrhythmics].
Topics: Adrenergic beta-Antagonists; Alprenolol; Anti-Arrhythmia Agents; Aspirin; Dipyridamole; Female; Fibr | 1981 |
[Prevention of myocardial infarction by chemotherapy].
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Blood Platelets | 1982 |
Changing concepts of pathophysiology, prognosis, and therapy in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Coronary Vasospasm; Death, Sudden; Dipyridam | 1983 |
Antiplatelet agents: rationale and results.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Animals; Arachidonic Acids; Aspirin; Blood Plate | 1983 |
[Perspectives of the preventive treatment of patients after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Death, Sudden; Exercise Therapy; Humans; Myo | 1984 |
Bleeding associated with antithrombotic therapy.
Topics: 4-Hydroxycoumarins; Aspirin; Dextrans; Dipyridamole; Dose-Response Relationship, Drug; Fibrinolytic | 1980 |
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypas | 1982 |
[Platelet anti-aggregant drugs and ischemic cardiopathy: evaluation of the effect on platelet aggregation and on antithrombin III].
Topics: Adult; Anticoagulants; Antithrombin III; Arrhythmias, Cardiac; Clofibrate; Dipyridamole; Female; Hum | 1981 |
[News in cardiology].
Topics: Heart Diseases; Humans; Myocardial Infarction; Nifedipine; Sulfinpyrazone | 1983 |
Role of platelet-active drugs in coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Therapy, Co | 1983 |
[Current clinical results of antiplatelet medication].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease; Dipyridamole; D | 1984 |
[Blood platelets and myocardial infarction].
Topics: Aspirin; Blood Platelets; Dipyridamole; Epoprostenol; Humans; Myocardial Infarction; Platelet Aggreg | 1984 |
Presentation and analysis of the results of clinical trials in cardiovascular disease.
Topics: Aspirin; Clinical Trials as Topic; Disopyramide; Home Care Services; Hospitalization; Humans; Myocar | 1981 |
Selection and results of antiplatelet therapy in the prevention of stroke and myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clofibrate; Di | 1981 |
[Adult respiratory distress syndrome (ARDS) (author's transl)].
Topics: Adrenal Cortex Hormones; Alkalosis; Barotrauma; Humans; Hypoxia; Myocardial Infarction; Positive-Pre | 1981 |
[Myocardial infarct: secondary prevention with drugs and their effects].
Topics: Alprenolol; Aspirin; Dipyridamole; Humans; Myocardial Infarction; Prognosis; Sulfinpyrazone | 1980 |
The randomized clinical trial: bias in analysis.
Topics: Acute Disease; Alprenolol; Atenolol; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Huma | 1981 |
Myocardial infarction.
Topics: Anticoagulants; Aspirin; Blood Platelets; Death, Sudden; Dipyridamole; Fibrinolytic Agents; Humans; | 1981 |
Antiplatelet agents: their role in the prevention of sudden death.
Topics: Animals; Aspirin; Blood Platelets; Cell Survival; Clinical Trials as Topic; Coronary Circulation; Co | 1982 |
Role of blood platelets in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Clofibrate; Co | 1979 |
[Indications and uncertainties of antiaggregating agents].
Topics: Anticoagulants; Aspirin; Clofibrate; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregati | 1977 |
[Clinical application and evaluation of anti-platelet agents].
Topics: Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; | 1978 |
[Prophylactic value of platelet anti-aggregants in coronary disease].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Embolism; Hea | 1979 |
Antiplatelet agents: a review.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofi | 1979 |
Clinical trials in thrombosis: secondary prevention of myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Humans; Male; Myocardial Infarction; Prospe | 1976 |
Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Brain; Clofibrate; Dextrans; Dipyridamole; Humans; Ischemi | 1976 |
Antithrombotic drugs: part II.
Topics: Anabolic Agents; Ancrod; Animals; Aspirin; Blood Platelets; Clofibrate; Dextrans; Dipyridamole; Fibr | 1976 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
[Platelet antiaggregants in the treatment of arterial thrombosis].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Coronary Artery | 1991 |
Antiplatelet and anticoagulant therapy in acute myocardial infarction.
Topics: Aspirin; Dipyridamole; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Sulf | 1991 |
Role of platelet inhibitor therapy in myocardial infarction.
Topics: Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Sulfinpyrazon | 1989 |
[Platelet aggregation inhibitors in the prevention of myocardial infarction: the results of prospective studies].
Topics: Aspirin; Canada; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Dipyridamole; Drug | 1989 |
Secondary prevention of coronary events after myocardial infarction. Beta-blockers and/or anti-platelets: to whom, when and for how long. A review.
Topics: Adrenergic beta-Antagonists; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Myoca | 1985 |
Platelets and prostaglandins in sudden death: therapeutic implications.
Topics: Adrenergic beta-Antagonists; Animals; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis; Aspirin | 1985 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
Clinical trials of antiplatelet drug therapy in acute myocardial infarction, unstable angina, and aortocoronary bypass surgery.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Arte | 1987 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disea | 1986 |
Clinical aspects of antiplatelet therapy.
Topics: Angina Pectoris; Aspirin; Blood Coagulation Disorders; Clinical Trials as Topic; Dipyridamole; Femal | 1985 |
Platelet inhibition in the management of thrombosis.
Topics: Aspirin; Blindness; Blood Platelets; Cell Survival; Cerebrovascular Disorders; Dextrans; Dipyridamol | 1974 |
70 trials available for sulfinpyrazone and Cardiovascular Stroke
| Article | Year |
|---|---|
Sulphinpyrazone, aspirin, and uric acid.
Topics: Aspirin; Death, Sudden; Humans; Myocardial Infarction; Sulfinpyrazone; Uric Acid | 1980 |
The anturane reinfarction trial.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Death, Sudden; Humans; Myocardial Infarction; | 1980 |
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
Topics: Adrenergic beta-Antagonists; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascula | 1980 |
Prophylaxis of myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial Inf | 1981 |
[New aspects in the prophylaxis of myocardial reinfarction (author's transl)].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Clinical Trials as Topic; Fibrinolytic Agents; Humans; | 1982 |
Does sulphinpyrazone prevent recurrence of myocardial infarction?
Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Myocardial Infarction; Random Allocation; Rec | 1982 |
[Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Clinical Trials as Top | 1983 |
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypas | 1982 |
Decrease in renal function due to sulphinpyrazone treatment early after myocardial infarction.
Topics: Acute Kidney Injury; Aged; Clinical Trials as Topic; Creatinine; Double-Blind Method; Female; Humans | 1983 |
Role of platelet-active drugs in coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Therapy, Co | 1983 |
In vivo platelet hyperactivity and factor VIII related antigen increase long after myocardial infarction. A controlled effect of sulfinpyrazone.
Topics: Adult; Antigens; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; Factor VIII; Human | 1981 |
A pharmacokinetic and platelet function study of the combined administration of metoprolol and sulfinpyrazone to healthy volunteers.
Topics: Adult; Blood Platelets; Drug Therapy, Combination; Humans; Male; Metoprolol; Middle Aged; Myocardial | 1984 |
Sulfinpyrazone decreases epinephrine-induced platelet aggregation after myocardial infarction.
Topics: Clinical Trials as Topic; Double-Blind Method; Epinephrine; Female; Humans; Male; Middle Aged; Myoca | 1982 |
[Secondary prevention of ischemic cardiopathy with anti-platelet aggregates in the post-infarct patient. Review].
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation | 1982 |
[Sulfinpyrazone in the prevention of sudden death after myocardial infarction (author's transl)].
Topics: Adult; Aged; Death, Sudden; Female; Heart Arrest; Humans; Male; Middle Aged; Myocardial Infarction; | 1980 |
Haemostatic function changes in a trial on the secondary prevention of myocardial infarction with sulphinpyrazone.
Topics: Adult; Aged; Blood Coagulation Tests; Clinical Trials as Topic; Female; Hemostasis; Humans; Male; Mi | 1981 |
Sulphinpyrazone and renal function following myocardial infarction.
Topics: Adult; Aged; Creatinine; Double-Blind Method; Female; Humans; Kidney; Male; Middle Aged; Myocardial | 1983 |
Sulfinpyrazone in the prevention of sudden death after myocardial infarction.
Topics: Aged; Clinical Trials as Topic; Death, Sudden; Double-Blind Method; Female; Follow-Up Studies; Human | 1980 |
Sulphinpyrazone in the prevention of cardiac death after myocardial infarction.
Topics: Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; Heart Arrest; Humans; Myocardial I | 1980 |
Drugs & dosages: Anturane.
Topics: Clinical Trials as Topic; Humans; Myocardial Infarction; Sulfinpyrazone | 1980 |
Anturan: new use for an old drug.
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sudden; Humans; Myocardial Infarction; Sulfin | 1980 |
The anturane reinfarction trial.
Topics: Clinical Trials as Topic; Death, Sudden; Humans; Myocardial Infarction; Sulfinpyrazone | 1980 |
The anturane reinfarction trial.
Topics: Acute Kidney Injury; Clinical Trials as Topic; Humans; Myocardial Infarction; Sulfinpyrazone | 1980 |
The anturane reinfarction trial.
Topics: Clinical Trials as Topic; Death, Sudden; Humans; Myocardial Infarction; Sulfinpyrazone | 1980 |
FDA says no to anturane.
Topics: Anticoagulants; Clinical Trials as Topic; Death, Sudden; Humans; Legislation, Drug; Myocardial Infar | 1980 |
Aspirin and recurrent myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Humans; Male; Middle Aged; Myocardial Infar | 1980 |
Sulphinpyrazone.
Topics: Anticoagulants; Clinical Trials as Topic; Humans; Myocardial Infarction; Sulfinpyrazone | 1980 |
Secondary prevention of myocardial infarction--the present state of the ART.
Topics: Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial | 1980 |
Sulphinpyrazone in acute myocardial infarction: studies on cardiac rhythm and renal function.
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Creatinine; Double-Blind Method; Female; Humans; Mal | 1980 |
Preventing the second infarct.
Topics: Adult; Animals; Clinical Trials as Topic; Death, Sudden; Dogs; Electrocardiography; Exercise Therapy | 1980 |
Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon.
Topics: 4-Hydroxycoumarins; Aged; Aspirin; Clinical Trials as Topic; Female; Hemorrhage; Humans; Male; Middl | 1980 |
Selection and results of antiplatelet therapy in the prevention of stroke and myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clofibrate; Di | 1981 |
[The platelet inhibitor problem].
Topics: Aspirin; Blood Transfusion; Brain Ischemia; Clinical Trials as Topic; Female; Humans; Male; Myocardi | 1981 |
[The effect of sulfinpyrazone on the coagulation-inhibiting action of acenocoumarol].
Topics: Acenocoumarol; Adult; Aged; Arterial Occlusive Diseases; Blood Coagulation; Clinical Trials as Topic | 1981 |
The randomized clinical trial: bias in analysis.
Topics: Acute Disease; Alprenolol; Atenolol; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Huma | 1981 |
Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Collagen; Coronary Disease; Dipyridamo | 1981 |
The Anturane Reinfarction Trial: reevaluation of outcome.
Topics: Clinical Trials as Topic; Follow-Up Studies; Humans; Myocardial Infarction; Random Allocation; Resea | 1982 |
More on sulfinpyrazone after myocardial infarction.
Topics: Clinical Trials as Topic; Humans; Myocardial Infarction; Sulfinpyrazone | 1982 |
E.P.S.I.M., the French oral anticoagulant--aspirin trial in post-myocardial infarction patients: design, organization and quality control procedures.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Data Collectio | 1981 |
Antiplatelet agents: their role in the prevention of sudden death.
Topics: Animals; Aspirin; Blood Platelets; Cell Survival; Clinical Trials as Topic; Coronary Circulation; Co | 1982 |
The anturane reinfarction trial.
Topics: Aspirin; Blood Platelets; Death, Sudden; Female; Humans; Male; Myocardial Infarction; Placebos; Sulf | 1980 |
Role of blood platelets in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Clofibrate; Co | 1979 |
[Possibilities and limits of controlled clinical therapy studies for the demonstration of the effectiveness of antithrombotic therapy].
Topics: Adult; Anticoagulants; Aspirin; Clinical Trials as Topic; Dextrans; Dipyridamole; Dose-Response Rela | 1975 |
Anturane reinfarction trial.
Topics: Clinical Trials as Topic; Drug Evaluation; Humans; Myocardial Infarction; Placebos; Recurrence; Sulf | 1978 |
Controlled ex-vivo effect of sulfinpyrazone on platelet function of myocardial infarction patients.
Topics: Adult; Analysis of Variance; Blood Coagulation Tests; Blood Platelets; Clinical Trials as Topic; Dou | 1979 |
Internation Committee on Thrombosis and Haemostasis Basil, 8.-11. September 1974 Subcommittee on Clinical Investigations: Registry of prospective clinical trials.
Topics: Ancrod; Animals; Arterial Occlusive Diseases; Aspirin; Batroxobin; Clinical Trials as Topic; Fibrino | 1975 |
A controlled study of the effect of sulfinpyrazone on platelet survival and on platelet-bound 14C-serotonin release in patients with previous myocardial infarction.
Topics: Adult; Aged; Blood Platelets; Cell Survival; Cholesterol; Clinical Trials as Topic; Female; Humans; | 1979 |
Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. The Anturane Reinfarction Trial.
Topics: Aged; Blood Platelets; Clinical Trials as Topic; Death, Sudden; Depression, Chemical; Double-Blind M | 1978 |
Sulfinpyrazone after myocardial infarction.
Topics: Clinical Trials as Topic; Humans; Myocardial Infarction; Sulfinpyrazone | 1978 |
Myocardial re-infarction and sulphinpyrazone.
Topics: Aged; Clinical Trials as Topic; Humans; Middle Aged; Myocardial Infarction; Recurrence; Sulfinpyrazo | 1978 |
Sulfinpyrazone after myocardial infarction?
Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Myocardial Infarction; Recurrence; Sulfinpyra | 1978 |
[Clinical application and evaluation of anti-platelet agents].
Topics: Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; | 1978 |
Sulphinpyrazone (Anturan) after myocardial infarction.
Topics: Clinical Trials as Topic; Humans; Myocardial Infarction; Placebos; Sulfinpyrazone | 1979 |
Sulphinpyrazone (Anturan) after myocardial infarct.
Topics: Clinical Trials as Topic; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1979 |
Prevention of death from myocardial infarction by aspirin and other platelet active drugs.
Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction; Platelet Aggregation; Sulfinpyrazo | 1979 |
Clinical trials in thrombosis: secondary prevention of myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Humans; Male; Myocardial Infarction; Prospe | 1976 |
The current status of platelet suppressive drugs in the treatment of thrombosis.
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cardiac Catheterization; Cell Surviva | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
[Platelet aggregation inhibitors in the prevention of myocardial infarction: the results of prospective studies].
Topics: Aspirin; Canada; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Dipyridamole; Drug | 1989 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
A serial study of platelet reactivity throughout the first six months after myocardial infarction: its modification by sulphinpyrazone.
Topics: Adult; Aged; Arachidonic Acid; Arachidonic Acids; Blood Platelets; Clinical Trials as Topic; Double- | 1987 |
Clinical trials of antiplatelet drug therapy in acute myocardial infarction, unstable angina, and aortocoronary bypass surgery.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Arte | 1987 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disea | 1986 |
Clinical aspects of antiplatelet therapy.
Topics: Angina Pectoris; Aspirin; Blood Coagulation Disorders; Clinical Trials as Topic; Dipyridamole; Femal | 1985 |
[Anticoagulants and thrombocyte aggregation inhibitors in or following myocardial infarct].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Fibrinolytic A | 1985 |
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Double-Blind Method; Drug Ther | 1985 |
Secondary prevention of myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infar | 1985 |
[Eicosanoids, myocardial ischemia and sudden death].
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Coronary Disease; Cyclooxygenase I | 1985 |
96 other studies available for sulfinpyrazone and Cardiovascular Stroke
| Article | Year |
|---|---|
THE EFFECT OF SULFINPYRAZONE (ANTURAN) ON PLATELET ECONOMY AND BLOOD COAGULATION IN MAN.
Topics: Arthritis; Arthritis, Rheumatoid; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Drug | 1965 |
ACUTE ANAPHYLACTOID REACTION TO PROBENECID.
Topics: Anaphylaxis; Colchicine; Diagnosis, Differential; Drug Therapy; Gout; Myocardial Infarction; Probene | 1965 |
Enhanced platelet aggregability in dogs following myocardial infarction.
Topics: Animals; Blood Platelets; Carrier Proteins; Collagen; Coronary Vessels; Dipyridamole; Disease Models | 1977 |
Clinical trials of uric acid lowering for coronary heart disease risk reduction.
Topics: Clinical Trials as Topic; Coronary Disease; Humans; Hyperuricemia; Myocardial Infarction; Platelet A | 2006 |
Treatment of the patient after myocardial infarction. The last decade and the next.
Topics: Adrenergic beta-Antagonists; Aspirin; Death, Sudden; Exercise Therapy; Humans; Myocardial Infarction | 1980 |
Anturane works--but how?
Topics: Humans; Myocardial Infarction; Prostaglandins; Recurrence; Sulfinpyrazone | 1980 |
Placebo-controlled, double-blind clinical trials can impede medical progress.
Topics: Adrenergic beta-Antagonists; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Bl | 1980 |
[Symposium "The after care of myocardial infarct with the aggregation inhibitor ANTURAN 200 mg for the reduction of the mortality risk"].
Topics: Austria; Congresses as Topic; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1980 |
Antiplatelet drugs in the secondary prevention of myocardial infarction. One view of the present position.
Topics: Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Myocardial Infarction; Recurrence; | 1980 |
Reduction of mortality by sulphinpyrazone after experimental myocardial infarction in the rat.
Topics: Animals; Coronary Vessels; Male; Myocardial Infarction; Rats; Sulfinpyrazone; Time Factors | 1980 |
[Role of medical treatment in the rehabilitation of the coronary patient].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Heart Diseases; Humans; Myoc | 1981 |
[Prevention of recurrent myocardial infarct].
Topics: Adrenergic beta-Antagonists; Aspirin; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1981 |
[Infarction prophylaxis--prevention of the sudden heart death? An alternative].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Dipyridamole; Female; Heart Arrest; Humans; Ma | 1982 |
[Prevention of ischemic cardiopathy, with special reference to secondary prevention in the post-infarct period].
Topics: Adrenergic beta-Antagonists; Coronary Artery Bypass; Heart Failure; Humans; Hyperlipidemias; Hyperte | 1981 |
Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Di | 1982 |
[Treatment with sulfinpyrazone in comparison with ditazol. Use of dynamic ECG for the study of the cardiac rhythm in patients with recent acute myocardial infarction].
Topics: Adult; Aged; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Oxazoles | 1983 |
Therapeutic interventions in acute myocardial infarction. Survey of the ACCP Section on Clinical Cardiology.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Calcium Channel Blocke | 1984 |
Mortality after recovery from myocardial infarction.
Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Death, Sudden; Heart Failure; Humans; Myocardi | 1980 |
[Benefits and dangers of preventive thinking in medicine--prevention of thromboembolism].
Topics: Adult; Aspirin; Bandages; Blood Flow Velocity; Coumarins; Dextrans; Dihydroergotamine; Dipyridamole; | 1981 |
In vivo platelet activation following myocardial infarction and acute coronary ischaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Beta-Globulins; beta-Thromboglobulin; Blood Coagulation Diso | 1982 |
Antithrombotic treatment.
Topics: Ancrod; Aspirin; Cerebrovascular Disorders; Dextrans; Dipyridamole; Drug Administration Schedule; He | 1983 |
[Treatment of myocardial infarct with anticoagulants, thrombolytics, inhibitors of platelet aggregation and beta receptor blockaders].
Topics: Adrenergic beta-Antagonists; Aged; Anticoagulants; Aspirin; Coumarins; Dicumarol; Dipyridamole; Fibr | 1984 |
Effects of sulfinpyrazone, aspirin and propranolol on the isoproterenol-induced myocardial necrosis.
Topics: Animals; Aspirin; Body Weight; Creatine Kinase; Cyclic AMP; Heart; Isoproterenol; Male; Myocardial I | 1981 |
[Platelet antiaggregants in post-myocardial infarct patients: why, which and in what doses?].
Topics: Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence; Sulfinpyrazo | 1983 |
Impairment of renal function in post-myocardial infarct patients treated with sulfinpyrazone.
Topics: Acute Kidney Injury; Creatinine; Humans; Myocardial Infarction; Sulfinpyrazone | 1984 |
Acute renal failure secondary to sulfinpyrazone treatment after myocardial infarction.
Topics: Acute Kidney Injury; Humans; Male; Middle Aged; Myocardial Infarction; Sulfinpyrazone | 1984 |
Anticoagulants and platelet-active agents in the secondary prevention of coronary artery disease.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprostenol; Humans | 1982 |
[Sulfinpyrazone (Anturane)--new indication: myocardial infarct?].
Topics: Arrhythmias, Cardiac; Aspirin; Death, Sudden; Humans; Myocardial Infarction; Platelet Aggregation; S | 1980 |
The effect of prolonged treatment with sulphinpyrazone on thromboxane A2 and prostacyclin in man.
Topics: Adult; Blood Platelets; Cyclooxygenase Inhibitors; Epoprostenol; Female; Humans; Male; Myocardial In | 1982 |
Comparative effects of acetylsalicylic acid (ASA) and sulfinpyrazone on isoproterenol-induced heart damage.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Blood Urea Nitrogen; Creatine Kinase; Isoproterenol; | 1981 |
[The Anturan reinfarct study].
Topics: Aged; Coronary Disease; Death, Sudden; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pla | 1980 |
Myocardial infarction and aspirin.
Topics: Aspirin; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1980 |
Acute renal failure following sulfinpyrazone therapy.
Topics: Acute Kidney Injury; Humans; Male; Middle Aged; Myocardial Infarction; Sulfinpyrazone | 1982 |
[Present situation of therapy with platelet aggregation inhibitors].
Topics: Adult; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Middle Aged; | 1982 |
On the limitation of therapeutic intervention trials in ischemic heart disease: a clinician's viewpoint.
Topics: Angina Pectoris; Anticoagulants; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; | 1982 |
[Sulfinpyrazone-associated renal failure (author's transl)].
Topics: Acute Kidney Injury; Adult; Aged; Blood Urea Nitrogen; Creatinine; Female; Humans; Indomethacin; Mal | 1982 |
Renal dysfunction with sulphinpyrazone therapy.
Topics: Acute Kidney Injury; Humans; Myocardial Infarction; Sulfinpyrazone | 1982 |
Non oliguric acute renal failure after treatment with sulfinpyrazone.
Topics: Acute Kidney Injury; Humans; Male; Middle Aged; Myocardial Infarction; Sulfinpyrazone | 1982 |
Drug-induced renal failure.
Topics: Humans; Indomethacin; Kidney Failure, Chronic; Myocardial Infarction; Sulfinpyrazone | 1982 |
Effect of non-steroid anti-inflammatory drugs in experimental myocardial infarction in rats.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Coronary Vessels; Indomethacin; Male; Myocardial Infarct | 1981 |
Influence of sulfinpyrazone and naproxen on infarct size in the dog.
Topics: Animals; Constriction, Pathologic; Coronary Vessels; Dogs; Dose-Response Relationship, Drug; Female; | 1981 |
Protective effect of sulfinpyrazone against catecholamine metabolite adrenochrome-induced arrhythmias.
Topics: Adrenochrome; Animals; Arrhythmias, Cardiac; Blood Pressure; Catecholamines; Dose-Response Relations | 1981 |
Reduction in the severity of myocardial infarction by sulfinpyrazone.
Topics: Animals; Isoproterenol; Male; Myocardial Infarction; Myocardium; Rats; Sulfinpyrazone | 1981 |
Acute renal dysfunction due to sulfinpyrazone therapy in post-myocardial infarction cardiomegaly: reversible hypersensitive interstitial nephritis.
Topics: Aged; Heart Failure; Humans; Kidney Medulla; Male; Middle Aged; Myocardial Infarction; Nephritis, In | 1981 |
Sulphinpyrazone and myocardial infarction.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence | 1981 |
[Acute renal failure induced by sulfinpyrazone (author's transl)].
Topics: Acute Kidney Injury; Adult; Female; Humans; Male; Middle Aged; Myocardial Infarction; Sulfinpyrazone | 1981 |
Antiplatelet drugs after myocardial infarction.
Topics: Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregati | 1980 |
[Sulfinpyrazone following myocardial infarct].
Topics: Humans; Myocardial Infarction; Sulfinpyrazone; Time Factors | 1980 |
The anturane reinfarction trial.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Death, Sudden; Guinea Pigs; In Vitro Techniques; | 1980 |
Drug reduces incidence of sudden cardiac death.
Topics: Aged; Death, Sudden; Double-Blind Method; Drug Evaluation; Humans; Middle Aged; Myocardial Infarctio | 1980 |
Preventing death after myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence; Sulfinpyrazone | 1980 |
Studies of myocardial infarction.
Topics: Aspirin; Dipyridamole; Drug Combinations; Gastrointestinal Diseases; Humans; Myocardial Infarction; | 1980 |
[Sulfinpyrazone in the prevention of sudden cardiac death after myocardial infarct].
Topics: Anti-Arrhythmia Agents; Death, Sudden; Humans; Myocardial Infarction; Sulfinpyrazone | 1980 |
Drug trials in myocardial infarction. Lessons to be learned from the Anturane Reinfarction Trial.
Topics: Clinical Trials as Topic; Humans; Middle Aged; Myocardial Infarction; Research Design; Sulfinpyrazon | 1980 |
Post-infarct sudden deaths curbed by sulfinpyrazone.
Topics: Canada; Death, Sudden; Double-Blind Method; Humans; Myocardial Infarction; Random Allocation; Sulfin | 1980 |
Sulfinpyrazone after myocardial infarction.
Topics: Australia; Death, Sudden; Humans; Myocardial Infarction; Recurrence; Risk; Sulfinpyrazone | 1980 |
Deposition of human labeled platelets to damaged rabbit aorta before and after use of sulfinpyrazone in patients with acute myocardial infarction.
Topics: Animals; Aorta; Blood Platelets; Humans; In Vitro Techniques; Myocardial Infarction; Perfusion; Plat | 1980 |
Sulphinpyrazone in acute myocardial infarction.
Topics: Acute Kidney Injury; Humans; Kidney; Male; Myocardial Infarction; Prostaglandins; Sulfinpyrazone | 1980 |
Sulfinpyrazone after myocardial infarction: no decision yet.
Topics: Clinical Trials as Topic; Death, Sudden; Humans; Myocardial Infarction; Research Design; Sulfinpyraz | 1980 |
The FDA's critique of the anturane reinfarction trial.
Topics: Clinical Trials as Topic; Death, Sudden; Double-Blind Method; Humans; Myocardial Infarction; Placebo | 1980 |
[Sulfinpyrazone (Anturan) after myocardial infarction].
Topics: Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1980 |
Anturane reinfarction trial.
Topics: Clinical Trials as Topic; Humans; Myocardial Infarction; Sulfinpyrazone | 1981 |
[Anti-platelet-aggregating drugs. Clinical pharmacology and therapeutic use].
Topics: Aspirin; Blood Platelet Disorders; Brain Ischemia; Clofibrate; Coronary Disease; Dipyridamole; Human | 1980 |
[Effects of sulfinpyrazone on early ventricular fibrillation and 2d-phase arrhythmias in acute myocardial infarction (author's transl)].
Topics: Animals; Arrhythmias, Cardiac; Dogs; Myocardial Infarction; Sulfinpyrazone; Ventricular Fibrillation | 1980 |
Sulphinpyrazone after myocardial infarction.
Topics: Aged; Female; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1978 |
Sulphinpyrazone after myocardial infarction.
Topics: Animals; Coronary Disease; Humans; Myocardial Infarction; Rabbits; Sulfinpyrazone | 1978 |
Myocardial re-infarction and sulphinpyrazone.
Topics: Arrhythmias, Cardiac; Humans; Myocardial Infarction; Sulfinpyrazone | 1978 |
[The possible mechanism of action of sulfinpyrazone].
Topics: Allopurinol; Humans; Myocardial Infarction; Sulfinpyrazone | 1978 |
[Action mechanism and clinical indications for thrombocyte aggregation inhibitors].
Topics: Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Humans; Ischemic Attack, Transient; Myocard | 1979 |
Sulphinpyrazone and warfarin after myocardial infarction.
Topics: Drug Therapy, Combination; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone; Warfarin | 1979 |
The Anturane reinfarction trial.
Topics: Canada; Double-Blind Method; Evaluation Studies as Topic; Humans; Myocardial Infarction; Platelet Ag | 1979 |
Sulfinpyrazone after myocardial infarction.
Topics: Humans; Myocardial Infarction; Sulfinpyrazone | 1979 |
Sulphinpyrazone and warfarin after myocardial infarction.
Topics: Drug Combinations; Humans; Myocardial Infarction; Research Design; Sulfinpyrazone; Warfarin | 1979 |
Blood platelet function.
Topics: Animals; Blood Platelets; Cell Membrane; Collagen; Glycoproteins; Humans; Indium; Isotopes; Myocardi | 1979 |
[Antiplatelet drugs (author's transl)].
Topics: Aspirin; Blood Platelets; Clofibrate; Dipyridamole; Female; Humans; Hydroxychloroquine; Ischemic Att | 1979 |
Trials of antiplatelet drugs: some methodological considerations.
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Coronary Disease; Drug Therapy, Combination; Fem | 1979 |
Platelet suppressing drugs in arterial disease.
Topics: Anticoagulants; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Humans; Myocardial | 1978 |
New job for an old drug?
Topics: Blood Platelets; Death, Sudden; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone; Time Fact | 1978 |
Sulphinpyrazone, cardiac infarction, and the prevention of death: a successful trial or another tribulation?
Topics: Humans; Myocardial Infarction; Recurrence; Research Design; Sulfinpyrazone | 1978 |
Sulphinpyrazone after myocardial infarction.
Topics: Arrhythmias, Cardiac; Humans; Myocardial Infarction; Sulfinpyrazone | 1978 |
Antiplatelet agents in coronary disease: are they of prophylactic value?
Topics: Angina Pectoris; Aspirin; Cardiopulmonary Bypass; Clofibrate; Coronary Disease; Dipyridamole; Fibrin | 1978 |
Sulphinpyrazone and prevention of death after myocardial infarction.
Topics: Humans; Myocardial Infarction; Myocardium; Research Design; Sulfinpyrazone | 1978 |
[Platelet inhibitory agents in the prevention of infarct].
Topics: Aspirin; Blood Platelets; Humans; Myocardial Infarction; Sulfinpyrazone | 1978 |
Effect of drugs of platelets and complications of vascular disease.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clofibrate; Coronary Disease; | 1977 |
Are agents affecting platelet function clinically useful in patients with coronary artery disease?
Topics: Angina Pectoris; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clofibrate; Coro | 1976 |
[Strategies for antiplatelet therapy-drug-fixed method and suppression-fixed method].
Topics: Aspirin; Cerebral Infarction; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infarction | 1992 |
[Antiplatelet therapy in cardiac diseases].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Humans; Mitral Valve Prolapse; Myoc | 1992 |
Anturan for secondary prophylaxis of myocardial infarction.
Topics: Adrenergic beta-Antagonists; Diuretics; Drug Therapy, Combination; Female; Glucosides; Humans; Male; | 1988 |
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate; | 1985 |
Electrophysiologic and antiarrhythmic actions of sulphinpyrazone and its sulfide metabolite G25671.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Disease; Cyclooxygenase Inhibitors; Dogs; Electrophysiolog | 1987 |
Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Combinatio | 1988 |
[Use of anturan in patients with ischemic heart disease with a history of acute myocardial infarction].
Topics: Coronary Disease; Coronary Thrombosis; Humans; Male; Myocardial Infarction; Platelet Aggregation; Pl | 1987 |
[Mode of action and clinical evaluation of platelet aggregation inhibitors].
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Graft Occlusion, Vascular; Humans; Ketanserin; Myo | 1987 |
Platelet aggregation and atherosclerosis.
Topics: Arteriosclerosis; Aspirin; Dipyridamole; Electrocardiography; Humans; Male; Middle Aged; Myocardial | 1986 |
[Prostaglandin studies in normal subjects and in post-myocardial infarct patients].
Topics: Adult; Aspirin; Child; Dinoprost; Female; Humans; Indomethacin; Male; Myocardial Infarction; Physica | 1985 |
[Incidence of thrombosis and the status of coagulation in ischaemic heart disease].
Topics: Acute Disease; Aspirin; Blood Coagulation; Chronic Disease; Coronary Disease; Depression, Chemical; | 1974 |